Sterility test filtration: assembly and aseptic controls

In membrane filtration sterility testing, the result also depends on the sample pathway. An incorrect connection can introduce contamination; an incompatible material or inhibitory residue can impair recovery. The useful question is: does the actual assembly preserve both aseptic control and method performance?

Choosing filtration or direct inoculation is covered separately. Here we follow components, transfers and controls without prescribing universal pore sizes, volumes, washes or incubation conditions.

1. Define the system and its boundary

Map the pathway from the sample container to the membrane and culture vessel. Include sampling points, adapters, tubing, vents, drains, pumping devices and isolator interfaces. Identify where the pathway remains closed and where aseptic manipulation is required. Calling an assembly a “closed system” does not eliminate risks at initial connections or during later interventions.

Analytical filtration retains microorganisms to be detected by the test method. It is not manufacturing sterilizing filtration: objectives, demonstrations and criteria are not interchangeable. Do not automatically transfer production filter tests or requirements to the analytical assembly.

2. Verify compatibility and configuration

Relate membrane, tubing, seal and container selection to the matrix and intended use. Consider viscosity, particulates, adsorption of product constituents, potential leachables and possible effects on growth. No material suits every formulation. A chemical compatibility chart is useful but does not establish microbial recovery by itself.

Compare the approved component list, pathway drawing, instruction version and actual assembly. Check that connections and capacities suit the method and equipment's stated limits. Specify which substitutions have already been assessed and which require change control; external resemblance is not evidence of equivalence.

3. Check receipt and status before use

At receipt, connect item code, batch, expiry, declared sterilization status and acceptance documents. Record relevant transport or storage conditions and inspect packaging, seals and protective barriers. Damaged packaging requires a documented material decision, not simply external cleaning.

Before testing, the analyst checks availability of the approved configuration, equipment suitability and consumable status. Laboratory management ensures necessary evidence is available; Quality participates according to site responsibilities. Avoid opening packages for checks that can be performed without compromising the barrier.

4. Control assembly and transfers

The operating sequence must come from the approved procedure and applicable instructions. The following checklist helps assess their coverage without replacing them. Consider material positioning, access, contact with critical surfaces and manipulations after transfer into the protected environment.

• Before: sample identified; components and batches checked; packaging acceptable; permitted pathway and materials confirmed; analyst qualified.
• During: connections match the diagram; critical points protected; flow observed; interventions, alarms and interruptions recorded contemporaneously.
• After: vessels and samples reconciled; closures and identification checked; data and anomalies submitted for review; materials handled under the procedure.

5. Distinguish function, integrity and recovery

Mechanical function answers “does the system transfer liquid as intended?”. Integrity checks required by the system and method address leakage or compromised barriers. Microbiological suitability instead establishes that the sample in its intended configuration does not prevent detection of relevant microorganisms. None of these three forms of evidence automatically substitutes for another.

Rinses, dilutions and neutralizers must be justified by the method and suitability studies, including potential neutralizer toxicity. Chapter 3 of the FDA manual specifically addresses product inhibition and recovery. Its operating instructions are not a recipe transferable to every assembly.

Connect this evidence to growth promotion, relevant controls and environmental management. For isolator transfers, also assess compatibility with the biodecontamination cycle and potential residue effects on testing.

6. Manage anomalies without automatic restarts

Leaks, blockages, breakages and unexpected stops require protection of samples and data and involvement of the designated functions. Record when the problem appeared, the amount already processed, the affected segment, any exposures and actions taken. Restored flow does not establish that asepsis remained controlled.

Do not independently replace a part and restart while discarding the first test. Assessment must distinguish mechanical failure, compromised testing and impact on results or other samples. If growth occurs, follow the positive sterility test investigation pathway without automatically blaming the device.

7. Maintain the configuration throughout its life cycle

Simulated case. A disposable connector is proposed as equivalent to its predecessor. Its nominal diameter matches, but its material and internal geometry differ. The laboratory compares instructions, connections, product contact, isolator transfer and available studies. Successful assembly is insufficient: before authorised introduction, change control defines necessary compatibility, leak-tightness and method suitability checks.

The conclusion may restrict the connector to demonstrated suitable configurations, request further evidence or reject it. Document the rationale, update the component list and training, and establish how the new component is identified. Review trends in leaks, blockages and interventions: an increase following the change warrants assessment even if individual tests have shown no growth.

Return to the Microbiology and sterility testing hub to connect assembly, method and investigation.

Sources and access limitations

• FDA, Aseptic Processing, 2004, XI.A: recovery, laboratory controls and training.
• FDA, Pharmaceutical Microbiology Manual, revision 02 dated 25 August 2020, chapter 3: public copy; does not replace the approved method or FDA's current internal version.
• WHO, TRS 961, Annex 2, 2011: good practices for pharmaceutical microbiology laboratories.
• European Commission, EU GMP Annex 1, 2022, section 10: quality control and test limitations.
• USP 〈71〉 and EDQM 2.6.1, harmonisation status: public information; current full compendial texts not accessed, no specific clauses attributed.

Sources checked on 30 September 2026. The checklist, matrix and case are original GuideGxP educational material to adapt to the site's system.